BioMagnetic Solutions

Executive Summary

BioMagnetic Solutions develops and commercializes cGMP-grade ferrofluid-based cell selection technologies for immunomagnetic cell separation. Its hardware and reagent kits target researchers, clinicians, and cell & gene therapy manufacturers, aiming to simplify workflows and improve yields. As a portfolio company of Gamma Biosciences, it benefits from strategic support and access to a broad customer base. The company addresses the growing demand for scalable, high-quality tools in advanced therapy manufacturing, a market projected to expand significantly as more cell and gene therapies gain approval. Its ferrofluid platform offers advantages in consistency and ease of use over traditional magnetic bead systems, potentially reducing process development time and cost.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation cell selection system with enhanced throughput75% success
• Q4 2026Strategic partnership with a top-10 cell therapy developer for process integration60% success
• Q1 2027FDA 510(k) clearance for a diagnostic application of ferrofluid technology50% success